Jeffrey Michael Karp

Jeffrey Michael Karp

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Jeffrey Michael Karp

Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDaniel Rosenblum
Daniel Rosenblum
NJNitin Joshi
Nitin Joshi
WTWei Tao
Wei Tao
JKJeffrey M. Karp
Jeffrey M. Karp
Dan PeerDan Peer
Dan Peer
Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

23 February 2014 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JAJames A Ankrum
James A Ankrum
JOJoon Faii Ong
Joon Faii Ong
JKJeffrey M Karp
Jeffrey M Karp

1 March 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
JKJeffrey M. Karp
Jeffrey M. Karp
GTGrace Sock Leng Teo
Grace Sock Leng Teo

1 January 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
XYXiaolei Yin
Xiaolei Yin
BMBenjamin E. Mead
Benjamin E. Mead
HSHelia Safaee
Helia Safaee
RLRobert Langer
Robert Langer
JKJeffrey M. Karp
Jeffrey M. Karp
OLOren Levy
Oren Levy

1 March 2012 in Cell Stem Cell
Verified
Journal Article
Closed access
SRSudhir H. Ranganath
Sudhir H. Ranganath
OLOren Levy
Oren Levy
MIManeesha Inamdar
Maneesha Inamdar
JKJeffrey M. Karp
Jeffrey M. Karp

24 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
OLOren Levy
Oren Levy
RKRui Kuai
Rui Kuai
ESErika M. J. Siren
Erika M. J. Siren
DBDeepak Bhere
Deepak Bhere
YMYuka Milton
Yuka Milton
JKJeffrey M. Karp
Jeffrey M. Karp
To realize the potential of MSCs, bioengineering is needed to boost potency and control heterogeneity.